mHSPC VL

Treatment Decision Making for the Metastatic Hormone-Sensitive Prostate Cancer Patient Population - Alicia Morgans

Details
Charles Ryan interviews Alicia Morgans on her thoughts about treatment decision making in the metastatic hormone-sensitive prostate cancer (mHSPC) population and changes that are rapidly developing in this area. They review how studies such as CHAARTED, LATITUDE, and STAMPEDE have shaped the current options. The discuss the next sets of data that are expected to further expand treatment options in...

STAMPEDE Trial Updates in Prostate Cancer - Silke Gillessen

Details
(Length of Discussion: 12 min) Silke Gillessen and Alicia Morgans discuss recent data from the STAMPEDE trial. Local radiotherapy improving survival in metastatic prostate cancer with low disease burden and the subanalysis looking at the effects of abiraterone acetate plus prednisone in both high and low metastatic hormone-sensitive prostate cancer. Silke shares the clinical trial design and data...

A Review on Practice Informing Prostate Cancer Study Results - Christopher Sweeney

Details
(Length of Conversation: 18 min) Christopher Sweeney and Alicia Morgans review practice informing data released at the ESMO 2018 meeting from the GETUG 12, ERA 223, and STAMPEDE studies. Biographies: Christopher Sweeney, MBBS, Professor of Medicine, Harvard Medical School, Medical Oncologist, Dana-Farber Cancer Institute Alicia Morgans, MD, MPH Related Content: 12-Year Follow-Up of GETUG-12, A Pha...

Radical Prostatectomy for Patients with Oligometastatic Prostate Cancer - Robert Hamilton

Details
Robert Hamilton, a Staff Urologic Oncologist from Princess Margaret Cancer Centre in Toronto, Canada discusses radical prostatectomy for patients with oligometastatic prostate cancer. He overviews the clinical and biological rationale for radical prostatectomy in the oligometastases setting and highlights the role of novel imaging. He reviews four major PET tracers receiving a lot of attention: PS...
email news signup